HomeEventsAustralia’s Vaccine Value Chain Conference

Australia’s Vaccine Value Chain Conference

21st – 22nd May 2024Sydney, NSW
An exclusive thought leadership event, bridging the gaps in Australia’s vaccine ecosystem to maximise health impact and unlock the nation’s economic potential in global disease prevention.

Overview

Biointelect recently convened the inaugural Vaccine Value Chain Conference which was attended by 230 experts from across the vaccine community. This exclusive thought leadership event explored how we can bridge the gaps in Australia’s vaccine ecosystem to maximise health impact and unlock the nation’s economic potential in global disease prevention.
Location
Doltone House Hyde Park, Sydney, New South Wales, Australia
Time Start/End
8:00 am, 21st May – 5:30pm 22nd May

Gallery

Day 1

8:00am – 8:30am

Registration
Coffee, Tea and Refreshments

8:30am – 8:50am

Opening of the Conference
Welcome to Country and Opening Remarks

8:50am – 10:15am

Plenary 1:
The Vaccine Value Chain – What Do We Want for Australia?

10:15am – 10:45am

Morning Tea and Networking

10:45am – 12:00pm

Plenary 2:
Preclinical Vaccine Development Capabilities in Australia: Governance, Skills and Talent

12:00pm – 1:00pm

Lunch and Networking Event

1:00pm – 2:15pm

Plenary 3:
Clinical Trials and Infrastructure

2:15pm – 3:30pm

Plenary 4:
Manufacturing: Supply, Demand and Sustainability

3:30pm – 4:30pm

Afternoon Tea and Networking

4:00pm – 5:30pm

Plenary 5:
Enabling Policy and Regulation for Vaccines

6:00pm – 7:00pm

Pre-dinner Drinks
Venue: Strangers Foundation Room, NSW Parliament
Pre-dinner remarks:
Leah Goodman, CEO Biointelect & The Hon Anoulack Chantivong MP Minister for Innovation, Science and Technology

7:00pm – 10:00pm

Dinner and Evening Networking

Day 2

8:00am – 8:30am

Coffee, Tea and Refreshments

8:30am – 8:50am

Special Session:
How Can Australia Contribute to Advance CEPI’s 100 Day Mission and the Regional Vaccine Manufacturing Collaborative?

9:45am – 11:00am

Plenary 6:
Equity of Access and Uptake

11:00am – 11:30am

Morning Tea and Networking

11:30am – 12:45pm

Plenary 7:
Market Access and Health Technology Assessment

12:45pm – 1:45pm

Lunch and Networking Event

1:45pm – 3:00pm

Plenary 8:
Funding and Investment

3:00pm – 3:40pm

Plenary 9:
Bringing it All Together/The Vaccine Value Chain

3:40pm – 3:50pm

Closing Remarks

4:15pm – 5:30pm

CSIRO Satellite Session:
Advancing Innovation in Australian Veterinary Vaccines

Sessions

Day 1

Opening Remarks

Jennifer Herz
Co-founder and Director, Biointelect
Brett Sutton
Director of Health & Biosecurity at CSIRO, Australia’s national science agency.

Recorded Presentation

The Hon Ged Kearney MP
Assistant Minister for Health and Aged care
Vaccine Value Chain and Global Ecosystem

Vaccine Value Chain and Global Ecosystem.pdf

Speakers
Eric Claaasen
Chief Executive Officer, Vironovative BV
Linda van de Burgwal
Associate Professor Societal Entrepreneurship and Innovation in Health and Life Sciences, Athena – Research and Education Institute
BactiVac – The UK-based global Network accelerating the development of vaccines against AMR-relevant bacterial pathogens

BactiVac – The UK-based global Network accelerating the development of vaccines against AMR-relevant bacterial pathogens.pdf

Adam Cunningham
Co-Director, Bacterial Vaccine Network (BactiVac)
Australian Value Vaccine Chain

Australian Value Vaccine Chain.pdf

Speakers
Jennifer Herz
Co-founder and Director, Biointelect
Esther Pronker
Consultant, Biointelect
The UK Vaccine Network and Comparison with Australia

The UK Vaccine Network and Comparison with Australia.pptx

Alex Spencer
Immunology Lecturer, University of Newcastle
Overseas Example CARB-X Accelerator and Learnings

Overseas Example CARB-X Accelerator and Learnings.pdf

Speakers
Richard Alm
Chief Scientist Officer, Carb-X
What’s New in Optimising Preclinical Vaccine Research

What’s New in Optimising Preclinical Vaccine Research.pdf

Speakers
Deborah Burnett
Group Leader, Garvan Institute of Medical Research
Collaborative Research Between Academic and Industry Scientists Drives Vaccine Development

Collaborative Research Between Academic and Industry Scientists Drives Vaccine Development.pdf

Speakers
Tony Cunningham
Director, Centre for Virus Research, The Westmead Instiute for Medical Research
Health Security Systems Australia: Reflections from Medical Countermeasures Program and Australian Capability Audit
Speakers
Felicia Pradera
Head, Health Security Systems Australia
Attracting Industry Investment in R&D, the Translational Science Hub as an Example

Translational Science Hub.pdf

Speakers
Iris Depaz
Managing Director Translational Science Hub, Sanofi
Clinical Development Challenges in Global Clinical Trials, What Do Sponsors Look For?

Strategic Clinical Development.pdf

Speakers
Cheryl Keech
Consultant in Strategic Clinical Development
Australia’s Strengths in Early Phase Trials and Capability Gaps

Australia’s Strengths in Early Phase Trials and Capability Gaps.pdf

Speakers
Paul Griffin
Director of Infectious Disease, Mater Hospital
Australian Capability and Contribution to Clinical Trials

Australian Capability and Contribution to Clinical Trials.pdf

Speakers
Peter Richmond
Head, Vaccine Trials Group, Telethon Kids Institute
Regional Clinical Trial Capability and Impact on Policy in Asia-Pacific

Regional Clinical Trial Capability and Impact on Policy in Asia-Pacific.pdf

Speakers
Fiona Russell
Group Leader Asia-Pacific Health Research, Murdoch Children’s Research Institute
Perspective on the Government Investment and Current/Planned Australian Manufacturing Capability

Perspective on the Government Investment and Current/Planned Australian Manufacturing Capability.pdf

Speakers
Louise Talbot
General Manager, Industry and Manufacturing Division, Department of Industry, Science and Resources
Local Manufacturer’s Perspective on Supply, Demand, and Sustainability

Local Manufacturer’s Perspective on Supply, Demand, and Sustainability.pdf

Speakers
Chris Larkins
Vice President – Operation, CSL Seqirus
Global Supply Chain Perspective on Supply, Demand, and Sustainability

Global Supply Chain Perspective on Supply, Demand, and Sustainability.pdf

Speakers
Andrew Watson
Director, CBE Pty Ltd
Biotech Perspective on Supply, Demand, Sustainability and Logistics of Delivery

Biotech Perspective on Supply, Demand, Sustainability and Logistics of Delivery.pdf

Speakers
Angus Forster
Chief Technology Officer, Vaxxas
Australia’s Vaccination Space: Exciting Developments and What We Have Learned from the Pandemic
Speakers
Paul Kelly
Chief Medical Officer, Australian Government Department of Health and Aged Care
The Platform Approach for Facilitating Vaccine Development and Regulation: MRNA as an Example

The Platform Approach for Facilitating Vaccine Development and Regulation.pdf

Speakers
John Skerritt
Enterprise Professor for Health Research Impact, University of Melbourne
Vaccine Surveillance and Vaccine Safety

Vaccine Surveillance and Vaccine Safety.pdf

Speakers
Kristine Macartney
Director, National Centre for Immunisation Research & Surveillance
Industry Perspectives on Pandemic Learnings and Enabling Regulatory Pathways

Industry Perspectives on Pandemic Learnings and Enabling Regulatory Pathways.pdf

Speakers
Carolyn Tucek-Szabo
Senior Director Global Regulatory Sciences Lead Australia/New-Zealand, Moderna
Animal Health Vaccines: Regulatory Barriers and Opportunities for Alignment

Animal Health Vaccines: Regulatory Barriers and Opportunities for Alignment.pdf

Speakers
Ben Stapley
Chief Executive Officer, Animal Medicines Australia

Day 2

Australia Case Study Series
Update from CEPI (Recorded presentation)
Speakers
Frederik Kristensen
Managing Director Regionalized Vaccine Manufacturing Collaborative (RMVC)
Case Study One

Case Study One.pdf

Speakers
Keith Chappell
Professor, Australian Insitute for Bioengineering and Nanotechnology, The University of Queensland
Case Study Two

Case Study Two.pdf

Speakers
Jamie Triccas
Deputy Director, Sydney Infectious Diseases Institute, The University of Sydney
Case Study Three

Case Study Three.pdf

Speakers
Anne Collins
Chief Executive Officer, Sementis
Improving Vaccine Confidence, Equity and Uptake (in Australia and the Asia Pacific region)

Improving Vaccine Confidence, Equity and Uptake.pdf

Speakers
Margie Danchin
Group Leader, Vaccine Uptake, MCRI in addition to Deputy Chair, ARIA
Strategies to Increase Vaccine Uptake in Primary Care

Strategies to Increase Vaccine Uptake in Primary Care.pdf

Speakers
Nigel Stocks
Director, Australian Sentinel Practices Research Network
Pharmacy Role in Increasing Adult Vaccine Uptake

Pharmacy Role in Increasing Adult Vaccine Uptake.pdf

Speakers
Chris Campbell
General Manager, Policy and Program Delivery, Pharmaceutical Society of Australia
Achieving Equity in Underserved Populations

Achieving Equity in Underserved Populations.pdf

Speakers
Kristy Crooks
Aboriginal Program Manager and leads Public Health Aboriginal Team, Health Protection – Hunter New England
Perspectives on How Vaccines are Valued

Perspectives on How Vaccines are Valued.pdf

Speakers
Natalie Carvalho
Associate Professor of Health Economomics, Melbourne School of Population and Global Health, University of Melbourne
Clinical Research Perspectives on HTA, Value of Vaccines and Evidence Generation
Speakers
Michelle Giles
Professor, Department of Infectious Disease, University of Melbourne
Industry Perspectives On HTA Review Priorities for Vaccines

Industry Perspectives On HTA Review Priorities for Vaccines.pdf

Speakers
Andrew Thirlwell
Global Policy and Public Affairs, Australia, New-Zealand and Korea Lead, Pfizer
Reflections: PBAC, HTA and Vaccines
Speakers
Michelle Burke
PBAC Member
Medical Research Future Fund Update
Speakers
Pru Glasson
Director Translation and Commercialisation Section, Australian Government Department of Health and Aged Care
How Industry Makes Investment Decisions

How Industry Makes Investment Decisions.pdf

Speakers
Patrick Desbiens
Senior Vice President & General Manager Australia, GSK
Accelerating Vaccines with Limited Commercial Potential, the Strep A Example

Accelerating Vaccines with Limited Commercial Potential, the Strep A Example.pdf

Speakers
Jonathan Carapetis
Executive Director, Telethon Kids Institute
Global Venture Capital and Private Equity Investment

Global Venture Capital and Private Equity Investment.pdf

Speakers
Eric Claassen
Chief Executive Officer, Vironovative BV
Panel Discussion
Panelists
Jodie McVernon
Professor and Director of Doherty Epidemiology
Kylie Sproston
Chief Executive Officer, Bellberry Limited
Sue MacLeman
Advisor and Non Executive Director, Medical Technology and Pharmaceutical (MTP)
Ian Henderson
Executive Director, Institute for Molecular Bioscience, University of Queensland
Chris Smith
Partner, Brandon Capital
Experience of SMEs in Australia’s Veterinary Vaccine Space
Speakers
Robin Achari
Senior Technical Veterinarian, Bioproperties
Experience of Multinational Companies in Australia’s Veterinary Vaccine Space
Speakers
Kishore Prayaga
Director, Veterinary Medicine R&D, Zoetis
Development and Negotiations for New Veterinary Vaccine Technologies – EMAI/NSW DPI mRNA Vaccine Project
Speakers
Paul Hick
Research Coordinator, Veterinary Virology, Elizabeth Macarthur Agricultural Institute (EMAI), NSW Department of Primary Industries (NSW DPI)
Biosecurity Policy Review: A Secure Future for Imports of Veterinary Vaccines
Speakers
Nathan Jamieson
Director, Department of Agriculture, Fisheries and Forestry (DAFF) Animal and Biological Import Branch
Regulatory Approaches for Veterinary Vaccine Platform Technologies – Challenges and Opportunities
Speakers
Mariette van Den Berg
Assistant Director Veterinary Medicines, Australian Pesticides and Veterinary Medicines Authority

Sponsors

Download Your PDF

To access the PDF, please fill out the form below. Once completed, you’ll be redirected to our folder where you can download all available resources.

Please enable JavaScript in your browser to complete this form.